Oral CCR5 inhibitors: will they make it through? (Q36458354)

14 August 2017

1 reference

title

Oral CCR5 inhibitors: will they make it through? (English)

1 reference

14 August 2017

5

Giuseppe Tambussi

1 reference

14 August 2017

1

Priscilla Biswas

1 reference

14 August 2017

Silvia Nozza

2

0 references

Gabriella Scarlatti

object named as

Gabriella Scarlatti

series ordinal

3

0 references

Adriano Lazzarin

object named as

Adriano Lazzarin

series ordinal

4

0 references

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Expert Opinion on Investigational Drugs

14 August 2017

published in

1 reference

14 August 2017

volume

15

1 reference

14 August 2017

issue

5

1 reference

14 August 2017

page(s)

451-464

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

The entry of entry inhibitors: a fusion of science and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

HIV and the chemokine system: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Emerging drug targets for antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Enfuvirtide: the first HIV fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Progress in targeting HIV-1 entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Co-receptor antagonists as HIV-1 entry inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

The clinical potential of chemokine receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: are they the next novel therapies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Chemokine receptors: gateways to inflammation and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Change in coreceptor use correlates with disease progression in HIV-1--infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Replicative fitness of CCR5-using and CXCR4-using human immunodeficiency virus type 1 biological clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

The HIV coreceptor switch: a population dynamical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

The greater chemotactic network for lymphocyte trafficking: chemokines and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

The chemokine system: redundancy for robust outputs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Structure-function studies of the HIV-1 coreceptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Assessing chemokine co-receptor usage in HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Increased replication of T-cell-tropic HIV strains and CXC-chemokine receptor-4 induction in T cells treated with macrophage inflammatory protein (MIP)-1alpha, MIP-1beta and RANTES beta-chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Punica granatum (pomegranate) juice provides an HIV-1 entry inhibitor and candidate topical microbicide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

HIV's response to a CCR5 inhibitor: I'd rather tighten than switch!

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Molecular mapping of epitopes for interaction of HIV-1 as well as natural ligands with the chemokine receptors, CCR5 and CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Effects of HIV-1 entry inhibitors in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Getting to the guts of HIV pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

CD8+ T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Double doors and gatekeepers: HIV co-receptors and chemokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

T cell costimulation by chemokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

HIV swiftly guts the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.5.451

10.1517/13543784.15.5.451

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference